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ABSTRACT
Patients in pediatric oncological hospitals are at risk of developing a Clostridium difficile infection. The purpose of this study was 
to determine the risk of developing a Clostridium difficile infection in patients who are treated with antibiotics of different classes 
and their combinations by way of a retrospective analysis of 122 patient records. It was shown that the administration of anti-
bacterial chemotherapeutic drugs that belong to the classes of nitrofurans (enterofuryl), sulfonamides (biseptol), cephalosporins, 
and macrolides/azalides significantly increased the risk of developing a Clostridium difficile infection in pediatric patients. On the 
contrary, treatment with antibiotics of different classes, such as linezolid, colistin, and metronidazole, significantly reduced the 
risk of developing a Clostridium difficile infection. The use of penicillins, aminoglycosides, fluoroquinolones, glycopeptides, and 
carbapenems was not associated with the risk of developing a Clostridium difficile infection in pediatric patients. The administra-
tion of one or two antimicrobial drugs of different classes increased the risk of developing a Clostridium difficile infection while a 
combination of three different types of antimicrobial drugs lowered the rate of this infection in pediatric patients.
INTRODUCTION
One side effect of antibiotics is the development of a mul-
tiple drug resistance of opportunistic microflora and the 
inhibition of the growth of indigenous human microflora. 
In these circumstances, conditionally pathogenic human 
microflora can cause serious diseases. Therefore, the pre-
dominance of Clostridium difficile (C. difficile) in the intes-
tinal microbiota can cause both mild disease and serious 
illnesses, such as pseudomembranous colitis, toxic mega-
colon, intestinal perforation, and intestinal bleeding [1]. 
C. difficile diarrhea has been the cause of increased mor-
bidity and mortality among hospitalized patients world-
wide since 2000 [2, 3]. According to the Centers for Disease 
Control and Prevention (CDC, USA), in the United States 
alone, there are more than 400,000 cases of C.  difficile 
infection with 29,000 fatalities every year [4]. Infections 
acquired in hospitals account for about two thirds of this 
amount. C. difficile is an anaerobic spore-forming Gram-
positive bacterium of the Peptostreptococcaceae family 
of the Clostridia class, which belongs to opportunistic 
microorganisms present in the colon that develop dur-
ing dysbiosis [5]. The development of a C. difficile infec-
tion is associated with the production of cellular toxins A 
(enterotoxin) and B (cytotoxin). These toxins bind to the 
surface of intestinal epithelial cells causing their death 
and lead to local inflammation [6].
A weakened immune status, disruption of the mucous 
membranes, and reduced conversion of primary bile salts 
into secondary ones observed in patients with impaired 
intestinal microflora are the main factors contributing to 
the disease [7]. Cancer patients who undergo anticancer 
chemotherapy and treatment with antimicrobial drugs 
over the course of long-term hospitalization have a high 
risk of developing a C. difficile infection [8-10]. According 
to Garzotto et al., one of the main factors in the develop-
ment of a C. difficile infection is treatment with antibiot-
ics rather than the type of tumor or anticancer therapy 
[11]. However, Anand et al. showed that cytotoxic chemo-
therapeutic agents themselves are capable of causing a 
C. difficile infection in the absence of antibiotics [12].
When treating children with an anticipated long stay 
in the hospital, it is common practice to supplement the 
main therapy with several groups of antibiotics [13]. Si-
multaneous administration of several antibiotics signifi-
cantly increases the risk of C. difficile infection in immu-
nosuppressed patients [14]. The objective of this study 
was to find the correlation between the administration 
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of different classes of antibiotics and their combinations 
with the incidence of a C. difficile infection in children in 
an oncological hospital.
MATERIALS AND METHODS
Patients and study design 
A retrospective observational study was carried out in an 
oncological hospital – Dmitry Rogachev National Medi-
cal Research Center of Pediatric Hematology, Oncol-
ogy, and Immunology in Moscow (NSPC PHOI, Russia). 
A  retrospective analysis of 122  patient records of chil-
dren aged 0 to 18 years was carried out including 48 cas-
es with diagnosed and confirmed C.  difficile antibiotic-
associated enterocolitis. The control group consisted of 
74 patients treated in the same hospital at the same time, 
but without symptoms of intestinal damage and with a 
negative test for toxins A and B in the feces. At the time 
of detection of a C. difficile infection, the patients were 
undergoing treatment for the main disease with the ad-
dition of the following antimicrobial chemotherapeutic 
drugs: nitrofurans (enterofuryl), sulfonamides (biseptol), 
cephalosporins, macrolides/azalides, aminoglycosides, 
carbapenems, penicillins, fluoroquinolones, lipopeptides 
(colistin), and oxazolidines (linezolid). The control group 
received the same drugs.
Confirmation of a C. difficile infection in patients was 
carried out by the detection of toxins A and B in feces 
using a competitive ELISA RIDASCREEN test system 
(R-Bio pharm, Germany).
The name and quantity of drugs used over the course 
of treatment of the main disease were recorded according 
to the patient’s medical history. All of the data were col-
lected and entered into a laboratory information system 
(SGM Analytix Explorer, Sweden). The statistical signifi-
cance of the results was assessed by the Pearson χ2 test at 
a significance level of p<0.05.
RESULTS AND DISCUSSION
Analyzing the results of the therapy of children – pa-
tients of the oncological hospital NSPC PHOI, we cal-
culated the frequency of C. difficile infections (by toxins 
A and B detection in the feces) in patients treated with 
different classes of antibacterial drugs. The results that 
are shown in Table 1 demonstrate a clear correlation be-
tween the use of antibacterial drugs that belong to the 
classes of nitrofurans, sulfonamides, cephalosporins, and 
macrolides/azalides and the development of a C. difficile 
infection in patients. 
Treatment with enterofuryl (class of nitrofurans, the 
first group of antibacterials (Table  1)) led to the high-
est rate (66%) of C. difficile infections in patients. Kumar 
et al. showed the highest frequency of formation of resis-
tant C. difficile mutants under the action of nitrofurans 
[15]. This effect explains the high probability of chang-
ing the microbiota composition in patients treated with 
drugs of the nitrofuran class due to the formation of re-
sistant forms of C. difficile that in turn can cause the de-
velopment of a pathological process.
Treatment with sulfonamides including biseptol – the 
second group of antibacterial drugs – led to less frequent 
development (55.1%) of C.  difficile infections. However, 
according to Zakharova et al., sulfonamides belong to the 
group of antimicrobials with a low risk of C. difficile in-
fection development. This discrepancy may be due to the 
wider use of biseptol in children undergoing treatment 
in an oncological hospital compared with other groups 
of patients [16].
Table 1. The incidence of C. difficile infection development depending on the class of ACDs co-administered in the course of treatment of 
the main disease compared with the control group.
Antibiotic classes Group size Frequency of C. difficile
infection occurrence, %
Statistical 
significance, pC. difficile infection Control group
Nitrofurans (enterofuryl) 4 2  66.7*** 0.000035
Sulfonamides (biseptol) 27 22  55.1** 0.0017
Cephalosporins 12 10  54.5** 0.0020
Macrolides/azalides 6 7  46.2* 0.022
Aminoglycosides 7 10 41.2 0.07
Carbapenems 11 17 39.3 0.12
Penicillins 7 17 29.2 0.7
Fluoroquinolones 4 11 26.7 1
Glycopeptides 9 26 25.7 0.8
Metronidazole 2 32  5.9### 0.00027
Polypeptide cyclic (colistin) 0 6  0### 0.00000024
Oxazolidines (linezolid) 0 5  0### 0.00000024
* – p<0.05, ** – p<0.01, *** – p<0.001 indicates the statistically significant increase in the incidence of a C. difficile infection in cases with the ad-
ministration of ACDs.
### – p<0.001 indicates the statistically significant decrease in the incidence of C. difficile infection in cases with the administration of ACDs.
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The administration of the drugs that belong to the 
third group – cephalosporin antibiotics – caused the de-
velopment of C. difficile infections in children at a lower 
rate of 54.5%. This finding is consistent with literature 
data based on the results of meta-analysis of studies that 
showed the strongest relationship between the third-
generation cephalosporins and C. difficile infections ac-
quired in hospitals (hospital-acquired infections, HAIs) 
[17, 18].
The fourth group of antimicrobials, which includes 
macrolide/azalide antibiotics, showed a statistically sig-
nificant correlation with the development of C. difficile 
infections in patients with the lowest rate of 46.2%, 
which agrees well with the literature data [18]. According 
to our data, the frequency of the C. difficile infection cas-
es after the treatment of patients with carbapenems did 
not have statistical significance that contradicts the data 
of Vardakas et al. [19]. This could probably be explained 
by choosing meropenem for our study – the antibacterial 
agent that has anti-anaerobic activity. 
Therefore, we have shown (Table  1) that the use of 
such antimicrobial chemotherapeutic drugs (ACDs) as 
nitrofurans, sulfonamides, cephalosporins, and mac-
rolides/azalides in children – patients of an oncologi-
cal hospital – was associated with the development of 
C.  difficile infection. The differences in their effect on 
patients are possibly related to the patient’s age and the 
course of treatment of the main disease.
Our data showed that the use of linezolid (group of 
oxazolidines) and colistin (a cyclic polypeptide antibi-
otic) significantly reduced the risk of C. difficile infection. 
This observation is consistent with the literature data on 
the activity of linezolid in vitro against C. difficile strains 
[20] and a low risk of developing a C. difficile infection 
over the course of treatment of patients with colistin 
[21]. In addition, it should be noted that, in our study, 
colistin was administered together with anti-anaerobic 
drugs, which reduces the risk of C. difficile infections.
Currently, two antimicrobial drugs registered for the 
treatment and prevention of C.  difficile infections are 
used in Russian pediatric oncological hospitals: vanco-
mycin and metronidazole [22]. It should be noted that, 
in our study, 2 patients developed a C. difficile infection 
while taking metronidazole and 9 patients – while treat-
ing the main disease with vancomycin. That could be ex-
plained by the emergence of C. difficile strains resistant 
to these drugs, and it could also be related to the route 
of administration of the drugs [23]. This issue requires a 
separate study. Since the problem of the treatment and 
prevention of C. difficile infection in a pediatric oncologi-
cal clinic remains relevant, it is necessary to search for a 
new approach to combat this illness.
To assess the risk of the C.  difficile infection devel-
opment due to the simultaneous administration of 2 or 
3 antibiotics, we compared the results from groups of pa-
tients treated with 2 or 3 drugs, group treated with 1 an-
tibiotic as well as a control group that was not treated 
with antimicrobials. Our results showed (Table 2) that the 
use of 1 drug or combination of 2 drugs in the treatment 
significantly increased the risk of C.  difficile infection 
development, while the simultaneous administration 
of 3 antibiotics reduced it. According to Lopes Cançado 
et  al., the amount of antibiotics used during hospital-
ization played a significant role in the development of 
C. difficile infections [24]. In our study, the reduced risk 
of C. difficile infections in cases where a combination of 
3 or more antibiotics were used for the treatment of the 
patients could be explained by the inclusion of an anti-
anaerobic component in this combination.
Therefore, the use of ACDs that belong to the follow-
ing classes – nitrofurans (enterofuryl), sulfonamides (bi-
septol), cephalosporins, and macrolides/azalides  – sig-
nificantly increased the risk of the C.  difficile infection 
development in children – patients of an oncological 
hospital. On the contrary, the treatment of pediatric pa-
tients with colistin, linezolid, and metronidazole signifi-
cantly reduced the risk of development of the C. difficile 
infection, whereas the use of penicillins, aminoglyco-
sides, fluoroquinolones, glycopeptides, and carbapenems 
was not associated with C.  difficile infection develop-
ment. The administration of one or two different classes 
of antimicrobials significantly increased the risk of the 
C.  difficile infection development. On the contrary, the 
simultaneous administration of 3 different classes of an-
timicrobial drugs reduced the risk of C. difficile infection 
development.
Table 2. Frequency of C. difficile infection depending on the number of ACDs co-administered in the course of treatment of the main disease
Frequency of C. difficile infection depending on the number of ACDs, %
0 ACD 1 ACD 2 ACDs 3 ACDs and more

















a – p value corresponding to an increase in the incidence of a C. difficile infection with the use of antimicrobial drugs compared with the group in 
which ACDs were not used. 
b – p value corresponding to a decrease in the incidence of a C. difficile infection with the use of ACDs compared to the group in which 1 ACD was 
used. 
c – p value corresponding to a decrease in the incidence of a C. difficile infection with the use of ACDs compared with the group in which 2 ACDs 
were used. 
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